SEC Comment Letter 0000000000-23-008698 to Connect Biopharma Holdings Ltd (CNTB)

Connect Biopharma Holdings Ltd
Date: Aug. 10, 2023 · CIK: 0001835268 · Accession: 0000000000-23-008698

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 001-40212

Date

August 10, 2023

Author

Zheng Wei, Ph.D.

Form

UPLOAD

Company

Connect Biopharma Holdings Ltd

Letter

United States securities and exchange commission logo August 10, 2023 Zheng Wei, Ph.D. Chief Executive Officer Connect Biopharma Holdings Limited 12265 El Camino Real, Suite 350 San Diego, CA 92130 Re:Connect Biopharma Holdings Limited Form 20-F for the Fiscal Year Ended December 31, 2022 File No. 001-40212 Dear Zheng Wei: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Steven Chan

Show Raw Text

United States securities and exchange commission logo
August 10, 2023
Zheng Wei, Ph.D.
Chief Executive Officer
Connect Biopharma Holdings Limited
12265 El Camino Real, Suite 350
San Diego, CA 92130
Re:Connect Biopharma Holdings Limited
Form 20-F for the Fiscal Year Ended December 31, 2022
File No. 001-40212
Dear Zheng Wei:
            We have completed our review of your filing.  We remind you that the company and its
management are responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       Steven Chan

SecProbe.io